Direxion Daily SandP Biotech Bull 3X Shares (LABU) |
| 164.89 -0.421 (-0.25%) 01-13 16:00 |
| Open: | 164.75 |
| High: | 166.7118 |
| Low: | 157.78 |
| Volume: | 633,871 |
| Market Cap: | 880(M) |
| PE Ratio: | 0 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 186.24 |
| Resistance 1: | 170.39 |
| Pivot price: | 165.82 |
| Support 1: | 144.75 |
| Support 2: | 120.43 |
| 52w High: | 186.245 |
| 52w Low: | 32.55 |
The fund invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments and securities of the index, exchange-traded funds ("ETFs") that track the index and other financial instruments that provide daily leveraged exposure to the index or ETFs that track the index. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Mon, 05 Jan 2026
LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF (NYSEARCA:LABU) - Seeking Alpha
Sun, 04 Jan 2026
Responsive Playbooks and the LABU Inflection - Stock Traders Daily
Wed, 24 Dec 2025
(LABU) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Mon, 22 Dec 2025
How to Trade Biotech’s Volatility with LABU/LABD | CRISPR & Cancer Stocks - ETFguide
Wed, 19 Nov 2025
Top Performing Leveraged/Inverse ETFs: 11/16/2025 - ETF Database
Fri, 19 Sep 2025
As M&A Deals Rise, Can Biotech Pharma Break Loose? - ETF Trends
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
